Vanessa M. Lucey, Ph.D., MBA

Director, CRI Venture Fund and Clinical Accelerator
New York | Email | (212) 688-7515 x244

Vanessa joined the CRI team in 2014 as a senior research analyst for the Clinical Accelerator program. She was the associate director for Clinical Accelerator from 2015-2018. She is now the director of Clinical Accelerator and the CRI Venture Fund where she leads and manages the program’s scientific and investment strategy for $100M evergreen venture fund. She also oversees and coordinates activities between our clinical trials management delivery partners, as well as various academic and biopharma stakeholders.

Prior to joining CRI, Vanessa performed research for 12 years as a scientist in immunology. She received her B.S. in Biology from Fordham University and prior to graduate school, Vanessa worked as a research technician studying the co-stimulatory molecule ICOS in Graft-versus-Host-Disease and Graft-versus-Leukemia. She received her Ph.D. from Albert Einstein College of Medicine studying T cell activation. She completed a postdoctoral fellowship at NYU School of Medicine, studying the role of a common gene variant and its effects on Graft-Versus-Host-Disease. Vanessa received her M.B.A. in Management/Finance from Mercy College School of Business. She has published 28 peer-reviewed papers in top tier journals. 

Select Publications

  • Tang J, Hubbard-Lucey VM, Pearce L, O’Donnell-Tormey J, Shalabi A. The global landscape of cancer cell therapy. Nature Reviews Drug Discovery. 10.1038/nrd.2018.74 (2018)  
  • Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2017 Dec 7. doi: 10.1093/annonc/mdx755. [Epub ahead of print]
  • Le DT, Hubbard-Lucey VM, Morse MA, Heery CR, Dwyer A, Marsilje TH, Brodsky AN, Chan E, Deming DA, Diaz LA, Fridman WH, Goldberg RM, Hamilton SR, Housseau F, Jaffee EM, Kang SP, Krishnamurthi SS, Lieu CH, Messersmith W, Sears CL, Segal NH, Yang A, Moss RA, Cha E, O'Donnell-Tormey J, Roach N, Davis AQD, McAbee KE, Worrall S, Benson AB. A Blueprint to Advance Colorectal Cancer Immunotherapies. Cancer Immunol Res. 2017 Oct 16. (PMID:29038296)
  • Mellman I, Hubbard-Lucey VM, Tontonoz MJ, Kalos MD, Chen DS, Allison JP, Drake CG, Levitsky H, Lonberg N, van der Burg SH, Fearon DT, Wherry EJ, Lowy I, Vonderheide RH, Hwu P. De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute.Cancer Immunol Res. 2016 Apr; 4 (4): 279-88. Review. (PMID: 27036972)
  • Hubbard-Lucey VM, Tontonoz MJ. Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference. Cancer Immunol Res January 2016 4; 3.
  • Hubbard-Lucey VM, Shono Y, Maurer K, West ML, Singer NV, Ziegler CG, Lezcano C, Motta AC, Schmid K, Levi SM, Murphy GF, Liu C, Winkler JD, Amaravadi RK, Rogler G, Dickinson AM, Holler E, van den Brink MR, Cadwell K. Autophagy Gene Atg16l1 Prevents Lethal T Cell Alloreactivity Mediated by Dendritic Cells. Immunity 2014 Oct 8.
  • Diab A, Jenq RR, Rizzuto GA, Cohen AD, Huggins DW, Merghoub T, Engelhorn ME, Guevara-Patiño JA, Suh D, Hubbard-Lucey VM, Kochman AA, Chen S, Zhong H, Wolchok JD, van den Brink MR, Houghton AN, Perales MA. Enhanced responses to tumor immunization following total body irradiation are time-dependent. PLoS One 2013 Dec 12.
  • Hubbard VM, Valdor R, Patel B, Singh R, Cuervo AM, Macian F. Macroautophagy regulates energy metabolism during effector T cell activation. J Immunol 2010 Dec 15.
  • Hubbard VM, Eng JM, Ramirez-Montagut T, Tjoe KH, Muriglan SJ, Kochman AA, Terwey TH, Willis LM, Schiro R, Heller G, Murphy GF, Liu C, Alpdogan O, van den Brink MR. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. Blood 2005 Nov 1.

Changing the Way Cancer is Treated and Cured

Let's spread the word about Immunotherapy! Click to share this page with your community.

*Immunotherapy results may vary from patient to patient.